Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 2/2004

01-04-2004 | Review Article

Levamisole in Dermatology

A Review

Authors: Dr Noah Scheinfeld, Joshua D. Rosenberg, Jeffrey M. Weinberg

Published in: American Journal of Clinical Dermatology | Issue 2/2004

Login to get access

Abstract

Levamisole, an anthelmintic agent with a wide range of immunomodulatory actions, has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Since 1990, combination therapy of levamisole and fluorouracil has played an important role in the treatment of resected Dukes stage C adenocarcinoma of the colon. Because of its immunomodulating effects levamisole has been used in a wide range of diseases with and without success. In dermatologic disease levamisole has been successfully used in the treatment of parasitic, viral and bacterial infections including leprosy, collagen vascular diseases, inflammatory skin diseases and children with impaired immune a variety of reasons. It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth. Adverse affects of levamisole are mild and infrequent and include rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia, and a flu-like syndrome. It can rarely cause agranulocytosis. More studies need to be undertaken to study the full potential of levamisole in dermatologic diseases.
Literature
1.
Assem ESK. Textbook of immunopharmacology. Dale MM, Foreman JC, editors. London: Blackwell Science Publications, 1984: 333–9
2.
Gennaro AR. Remington: the science and practice of pharmacy. 19th ed. Easton (PA): Mack Publishing Co., 1995: 101–2
3.
4.
Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000; 100: 217–24PubMedCrossRef
5.
Renoux G. The general immunopharmacology of levamisole. Drugs 1980; 19: 89–99CrossRef
6.
Sun A, Chiang CP. Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus. J Oral Pathol Med 2001; 30: 542–8PubMedCrossRef
7.
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8PubMedCrossRef
8.
Alsaran K, Grisaru S, Stephens D, et al. Levamisole vs cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2001; 56: 289–94PubMed
9.
Renoux G. Modulation of immunity by levamisole. J Pharmacol Ther 1978; 2: 288–96
10.
Sweetman SC. Martindale: the complete drug reference. 33rd ed. Chicago (IL): Pharmaceutical Press, 2002: 1253–4
11.
Roberts G. Levamisole. IPCS INCHEM Canada [online]. Available from URL: http://​www.​inchem.​org/​documents/​jecfa/​jecmono/​v33je02.​htm [Accessed 2004 Mar 19]
12.
Symoens J, Veys E, Mielants M, et al. Adverse reactions to levamisole. Cancer Treat Rep 1978; 62: 1721–30PubMed
13.
Hook CC, Kimmel DW, Kvols LK, et al. Mutlifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31: 262–7PubMedCrossRef
14.
Kimmel DW, Schutt AJ. Mutlifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993; 68: 363–5PubMedCrossRef
15.
Lucia P, Pocek M, Passacantando A, et al. Multifocal leukoencephalopathy induced by levamisole [letter]. Lancet 1996; 348: 1450PubMedCrossRef
16.
Secher L, Permin H, Skov PS, et al. Levamisole-induced hypersensitivity. Acta Derm Venereol 1978; 58: 372–4PubMed
17.
Kirby JD, Black M, McGibbon D. Levamisole-induced lichenoid eruptions. J R Soc Med 1980; 73: 208–11PubMed
18.
Clavere P, Bonnafoux-Clavere A, Delrous JL, et al. Fixed pigmented erythema caused by levamisole administration. Ann Dermatol Venereol 1994; 121: 238–9PubMed
19.
20.
Scheinberg MA, Bezerra JB, Almeida FA, et al. Cutaneous necrotising vasculitis induced by levamisole [letter]. BMJ 1978; 18: 408CrossRef
21.
Powell J, Grech H, Holder J. A boy with cutaneous necrosis occurring during treatment with levamisole. Clin Exp Dermatol 2002; 27: 32–3PubMedCrossRef
22.
Rongioletti F, Ghio L, Ginevri F, et al. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 1999; 140: 948–51PubMedCrossRef
23.
Menni S, Pistritto G, Gianotti R, et al. Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 1997; 14: 477–9PubMedCrossRef
24.
Papageorgiou P, Kesarwala HH, Alcid DV, et al. Levamisole in chronic pyoderma. J Clin Lab Immunol 1982; 8: 121–7PubMed
25.
Djawari D, Hornstein OP. Recurrent chronic pyoderma with cellular immunodeficiency: successful therapy by levamisole. Dermatologica 1980; 161: 116–23PubMedCrossRef
26.
Svejgaard E, Christiansen AH, Stahl D, et al. Clinical and immunological studies in chronic dermatophytosis caused by Trichophyton rubrum. Acta Derm Venereol 1984; 64: 493–500PubMed
27.
Butler PG. Levamisole therapy of chronic Leishmania tropica. J Trop Med Hyg 1978; 81: 221–4PubMed
28.
Paul Y, Singh J. Cutaneous larva migrans in an infant. Indian Pediatr 1994; 31: 1089–91PubMed
29.
Namazi MR. Levamisole: a safe and economical weapon against pediculosis. Int J Dermatol 2001; 40: 292–4PubMedCrossRef
30.
Raptopoulou GM, Kountouras J, Goulis G. Levamisole in the treatment of chronic brucellosis. J Immunopharmacol 1980; 2: 85–97
31.
Haneke E. Levamisole therapy under different dermatological indications. Z Hautkr 1979; 54: 408–14PubMed
32.
Russell AS, Brisson E, Grace M. A double-blind controlled trial of levamisole in the treatment of recurrent herpes labialis. J Infect Dis 1978; 137: 597–600PubMedCrossRef
33.
Constantopoulos A, Lagos P, Benetos S, et al. Disseminated neonatal herpes simplex infection treated with levamisole: report of a case. Dermatologica 1980; 160: 121–4PubMedCrossRef
34.
Smirnov IuK, Shishov AS, Bagrov FI, et al. Levamisole in the treatment of different forms of herpes zoster. Zh Nevropatol Psikhiatr Im S S Korsakova 1983; 83: 511–5PubMed
35.
Parsad D, Pandhi R, Juneja A, et al. Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. Pediatr Dermatol 2001; 18: 349–52PubMedCrossRef
36.
Parsad D, Saini R, Negi KS. Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts. Australas J Dermatol 1999; 40: 93–5PubMedCrossRef
37.
Amer M, Tosson Z, Soliman A, et al. Verrucae treated by levamisole. Int J Dermatol 1991; 30: 738–40PubMedCrossRef
38.
Saul A, Sanz R, Gomez M. Treatment of multiple viral warts with levamisole. Int J Dermatol 1980; 19: 342–3PubMedCrossRef
39.
Schou M, Helin P. Levamisole in a double-blind study: no effect on warts. Acta Derm Venereol 1977; 57: 449–54PubMed
40.
Patrone F, Dallegri F, Bonvini E, et al. Disorders of neutrophil function in children with recurrent pyogenic infections. Med Microbiol Immunol (Berl) 1982; 171: 113–22CrossRef
41.
Businco L, Laurenti F, Rossi P, et al. A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole. Arch Dis Child 1981; 56: 60–3PubMedCrossRef
42.
Verhaegen H, De Cree J, De Cock W, et al. Levamisole treatment of a child with severe aphthous stomatitis and neutropenia. Postgrad Med J 1976; 52: 511–4PubMedCrossRef
43.
Prakash MS, Rao VM, Reddy V. Effect of levamisole on the immune status of malnourished children. J Trop Pediatr 1998; 44: 165–6PubMedCrossRef
44.
Ellegaard J, Boesen AM. Restoration of defective cellular immunity by levamisole in a patient with immunoblastic lymphadenopathy: levamisole therapy for cellular immunologic deficiency with high IgE values. Scand J Haematol 1976; 17: 36–43PubMedCrossRef
45.
Sharma L, Thalliath GH, Girgia HS, et al. A comparative evaluation of levamisole in leprosy. Indian J Lepr 1985; 57: 11–6PubMed
46.
Bera DK, Sen PC. Effect of levamisole on bacterial index in BL and LL leprosy. Int J Lepr Other Mycobact Dis 1985; 53: 198–200PubMed
47.
Arora SK, Singh G, Sen PC. Immuno-stimulatory effect of levamisole in borderline leprosy cases. Indian J Lepr 1985; 57: 22–6PubMed
48.
Haneke E. Levamisole treatment of acne fulminans. Z Hautkr 1981; 56: 1160–6PubMed
49.
Lu SY, Chen WJ, Eng HL. Response to levamisole and low-dose prednisolone in 41 patients with chronic oral ulcers: a 3-year open clinical trial and follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86: 438–45PubMedCrossRef
50.
Lozada F, Silverman S, Cram D. Pemphigus vulgaris: a study of six cases treated with levamisole and prednisone. Oral Surg Oral Med Oral Pathol 1982; 54: 161–5PubMedCrossRef
51.
Mashkilleson NA. Exacerbation of the course of pemphigus vulgaris after taking levamisole. Vestn Dermatol Venerol 1980; Oct (10): 46–8
52.
Brzezinska-Wcislo L, Krauze E, Suwala-Jurczyk B. Levamisole in the treatment of crural ulcers. Przegl Dermatol 1990; 77: 51–5PubMed
53.
Jautova J, Jarcuskova D, Dubivska M, et al. Immunostimulation therapy in patients with alopecia areata. Bratisl Lek Listy 1995; 96: 160–4PubMed
54.
de Metieux P, Spitler LE, Paulus HE. Treatment of Behcet syndrome with levamisole. Arthritis Rheum 1981; 24: 64–70CrossRef
55.
Pachor ML, Bambara LM, Lunardi C, et al. Behcet’s syndrome: description of a clinical case. Minerva Med 1982; 73: 3411–6PubMed
56.
Lozada-Nur F, Cram D, Gorsky M. Clinical response to levamisole in thirty-nine patients with erythema multiforme: an open prospective study. Oral Surg Oral Med Oral Pathol 1992; 74: 294–8PubMedCrossRef
57.
Lozada-Nur F, Gorsky M, Silverman Jr S. Oral erythema multiforme: clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol 1989; 67: 36–40PubMedCrossRef
58.
Lozada F. Levamisole in the treatment of erythema multiforme: a double-blind trial in fourteen patients. Oral Surg Oral Med Oral Pathol 1982; 53: 28–31PubMedCrossRef
59.
Scherak O, Smolen J, Kolarz G, et al. Clinical experience with levamisole treatment of patients with systemic lupus erythematosus. Wien Klin Wochenschr 1979; 91: 758–62PubMed
60.
61.
Runge LA, Pinals RS, Tomar RH. Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes. Ann Rheum Dis 1979; 38: 122–7PubMedCrossRef
62.
Rondier J, Cayla J, Tron F, et al. Controlled trial of levamisole in rheumatoid arthritis: clinical and immunological study of 22 cases. Nouv Presse Med 1978; 7: 3023–7, 3029–30PubMed
63.
Basch CM, Spitler LE, Engleman EG, et al. Cellular immune reactivity in patients with rheumatoid arthritis and effects of levamisole. J Rheumatol 1977; 4: 377–88PubMed
64.
Huskisson EC, Scott J, Balme HW, et al. Immunostimulant therapy with levamisole for rheumatoid arthritis. Lancet 1976; I: 393–5CrossRef
65.
Veys EM, Mielants H, Verbruggen G. Goldsalts, levamisole and D-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis: a long-term follow-up study. Clin Exp Rheumatol 1987; 5: 111–6PubMed
66.
Lu SY, Chen WJ, Eng HL. Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus: a 6-year prospective follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80: 705–9PubMedCrossRef
67.
Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 1994; 33: 584–7PubMedCrossRef
68.
Sanchez MR. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine. Clin Dermatol 2000; 18: 131–45PubMedCrossRef
69.
Medvedev IuA, Alekhin EK, Leshchenko VM. Use of immunostimulants in the treatment of a zooanthroponotic trichophyton infection. Vestn Dermatol Venerol 1987; 11: 70–3PubMed
70.
Butler PG. Levamisole and immune response phenomena in cutaneous leishmaniasis. J Am Acad Dermatol 1982; 6: 1070–7PubMedCrossRef
71.
Makled M, Rifaat M, Azab M, et al. Determination of healing response by immunostimulant therapy (levamisole) in cutaneous leishmaniasis. Chemioterapia 1987; 6 (2 Suppl.): 214–6PubMed
72.
Chong H. Oriental sore: a look at trends in and approaches to the treatment of leishmaniasis. Int J Dermatol 1986; 25: 615–23PubMedCrossRef
73.
Mukovozova LA. Effect of levamisole on the cellular and humoral immunity indices in patients with chronic brucellosis. Zh Mikrobiol Epidemiol Immunobiol 1988; 10: 45–9PubMed
74.
Mukovozova LA. Effect of levamisole on the cellular immunity indices of patients with active forms of brucellosis. Zh Mikrobiol Epidemiol Immunobiol 1988; 6: 61–5PubMed
75.
Thornes RD. Chronic human brucellosis and anti-anergic treatment with levamisole. Vet Rec 1977; 101: 27–30PubMedCrossRef
76.
Katzung BG. Basic and clinical pharmacology. 8th ed. Norwalk (CT): Lange Medical Books/McGraw Hill, 2001
77.
National Center for Infectious Diseases. Infectious disease index [online]. Available from URL: http://​www.​cdc.​gov/​ncidod/​index.​htm [Accessed 2003 Mar 26]
78.
Dale MM, Foreman JC, editors. Textbook of immunopharmacology. London: Blackwell Scientific Publications, 1984: 333–9
79.
Seidlin M, Straus SE. Treatment of mucocutaneous herpes simplex infection. Clin Dermatol 1984; 2: 100–16PubMedCrossRef
80.
Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrent-infection (Job’s) syndrome: a review of the NIH experience and the literature. Medicine 1983; 62: 195–208
81.
Vanheule R, De Cree J, Adriaenssens K, et al. Levamisole therapy for cellular immunologic deficiency with high IgE values. Acta Paediatr Belg 1976; 29: 41–6PubMed
82.
McManus AT. Examination of neutrophil function in a rat model of decreased host resistance following burn trauma. Rev Infect Dis 1983; 5 Suppl. 5: S898–907CrossRef
83.
Stinnett JD, Loose LD, Miskell P, et al. Synthetic immunomodulators for prevention of fatal infections in burned guinea pig model. Ann Surg 1983; 198: 53–7PubMedCrossRef
84.
Matachin EN, Atiasov NI, Zuev PD, et al. Methods of correction of humoral and cellular immunity in patients with burns and erosive-ulcerative lesions of the gastrointestinal tract. Vestn Khir Im I I Grek 1990; 144: 44–9
85.
Katoch K. Immunotherapy of leprosy. Indian J Lepr 1996; 68: 349–61PubMed
86.
Martinez D, Zaias N. Levamisole as adjunct to dapsone in leprosy. Lancet 1976; II: 209–10CrossRef
87.
Carli-Basset C, Renoux M, Pauley AM, et al. Correlation between the immune reaction and clinical course in a bullous pemphigoid case treated with levamisole. LARC Med 1982; 2 (5): 400–41
88.
Liapon AO, Rutshtein LG, Roitburd MF, et al. Levamisole (decaris) in the complex treatment of different clinical forms of psoriasis. Vestn Dermatol Venerol 1984; 4: 61–6PubMed
89.
Sehgal VN, Jain S, Kumar S, et al. Generalized lichen nitidus in a child’s response to cetirizine dihydrochloride/levamisol [letter]. Australas J Dermatol 1998; 39: 60PubMed
90.
91.
Lavery HA, Pinkerton JH. Successful treatment of Behcet’s syndrome with levamisole. Br J Dermatol 1985; 113: 372–3PubMedCrossRef
92.
Bang D. Treatment of Behcet’s disease. Yonsei Med J 1997; 38: 401–10PubMed
93.
Borrego LC, Escobar AS, Averhoff Casamayor MC, et al. Behcet’s syndrome: report of the first case in Cuba. Rev Cubana Estomatol 1989; 26: 175–80PubMed
94.
Wechsler B, Le Thi Huong DU, Godeau P. Medical treatment of Behcet’s disease. J Mal Vasc 1988; 13: 262–9PubMed
95.
Dhar S, Kanwar AJ, Ghosh S. Levamisole in erythema multiforme. Oral Surg Oral Med Oral Pathol 1993; 76: 678–9PubMedCrossRef
96.
Ogawa K, Sano T, Hisano G, et al. Levamisole in systemic lupus erythematosus. Ann Allergy 1979; 43: 187–9PubMed
97.
Smolen J, Scherak O, Menzel J, et al. Levamisole in systemic lupus erythematosus. Arthritis Rheum 1977; 20: 1558–9PubMedCrossRef
98.
Karchova TIu, Demin AA. The present-day treatment of systemic lupus erythematosus. Revmatologiia (Mosk) 1989; 4: 59–66
99.
Veys EM, Mielants H, Verbruggen G, et al. Levamisole as basic treatment of rheumatoid arthritis: long-term evaluation. J Rheumatol 1981; 8: 45–6PubMed
100.
Mowat AG. Levamisole and cellular immunity in rheumatoid arthritis: a review. J Rheumatol Suppl 1978; 4: 55–61PubMed
101.
Yunus MB. Investigational therapy in rheumatoid arthritis: a critical review. Semin Arthritis Rheum 1988; 17: 163–84PubMedCrossRef
102.
Balabanova RM, Barakat B. Immunomodulating therapy of rheumatoid arthritis. Revmatologiia (Mosk) 1990; 3: 38–44
103.
Hernandez-Perez E. Levamisole plus indomethacin in the treatment of herpes simplex. Dermatologica 1980; 160 (2): 118–20PubMedCrossRef
104.
Tanphaichitra D, Srimuang S. Efficacy of acyclovir combined with immunopotentiating agents in the treatment of varicella-zoster. J Antimicrob Chemother 1987; 19: 255–62PubMedCrossRef
105.
Glick M, Muzyka BC. Alternative therapies for major aphthous ulcers in AIDS patients. J Am Dent Assoc 1992; 123: 61–5PubMed
106.
Wiggington JM. Reversal of ferritin mediated immunosuppression by levamisole: a rationale for its application to the management of the acquired immune deficiency syndrome (AIDS). Med Hypotheses 1995; 44: 85–8CrossRef
107.
Bourinbaiar AS, Lee-Huang S, Krasinski K, et al. Anti-HIV effect of immunomodulating agent, levamisole, in vitro. Biomed Pharmacother 1994; 48: 327–30PubMedCrossRef
108.
White CR, Hanifin JM. Levamisole therapy in atopic dermatitis: Randomized double-blind evaluation. Arch Dermatol 1978; 114: 1314–5PubMedCrossRef
109.
Sachar DB, Rubin KP, Gumaste V. Levamisole in Crohn’s disease: a randomized, double-blind, placebo-controlled clinical trial. Am J Gastroenterol 1987; 82: 536–9PubMed
110.
Dickler MN, Coit DG, Meyers ML. Adjuvant therapy of malignant melanoma. Surg Oncol Clin N Am 1997; 6: 793–812PubMed
111.
112.
Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9: 736–40PubMed
113.
Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10: 325–8PubMed
114.
Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991; 9: 729–35PubMed
115.
Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75 (2 Suppl.): 726–34PubMedCrossRef
116.
Wanebo HJ, Hilal EY, Pinsky CM, et al. Randomized trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Cancer Treat Rep 1978; 62: 1663–9PubMed
117.
Olivari AJ, Glait HM, Guardo A, et al. Levamisole in squamous cell carcinoma of the head and neck. Cancer Treat Rep 1979; 63: 983–90PubMed
118.
Hazen PG, Kallor A, Michel B. Effects of levamisole in Sezary syndrome: apparent acceleration of disease. Dermatologica 1979; 159: 461–5PubMedCrossRef
119.
Arora SK, Singh G, Sen PC. Levamisole in cases of ENL. Indian J Lepr 1985; 57: 17–21PubMed
120.
Singh NK, Jha TK, Singh IJ, et al. Combination therapy in Kala-azar. J Assoc Physicians India 1995; 43: 319–20PubMed
121.
122.
123.
Cole PJ, Citron KM, Plowman PN, et al. The treatment of sarcoidosis by levamisole. Br J Dis Chest 1979; 73: 367–72PubMedCrossRef
124.
Folkers E, Tafelkruyer J. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease): therapeutic problems. Br J Dermatol 1978; 98: 681–4PubMedCrossRef
Metadata
Title
Levamisole in Dermatology
A Review
Authors
Dr Noah Scheinfeld
Joshua D. Rosenberg
Jeffrey M. Weinberg
Publication date
01-04-2004
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2004
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200405020-00004

Other articles of this Issue 2/2004

American Journal of Clinical Dermatology 2/2004 Go to the issue

Therapy in Practice

Prurigo

Adis Drug Profile

Topical Methyl Aminolevulinate

Adis Drug Profile

Topical Methyl Aminolevulinate

Adis Drug Profile

Topical Methyl Aminolevulinate

Review Article

Vulvar Lichen Sclerosus

Leading Article

Fixed-Dose Combination Therapy for Psoriasis